Skip to content

The Lack of Clinical Trials in the Medical Marijuana Industry

The Lack of Clinical Trials in the Medical Marijuana Industry

As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical marijuana to patients with a qualifying condition, but most feel they don’t have sufficient knowledge or feel comfortable to do so. This lack of knowledge is a direct result of the lack of clinical trials in the medical marijuana industry, but why is that the case?

The Problem

The biggest problem surrounding why it’s so difficult for scientists to get clinical trials up and running is the continuation of roadblocks that federal laws create. Even though medical marijuana may be legalized in some states, scientists are still having a significantly harder time conducting research on the medicinal benefits of this “illicit drug”. Without sufficient research, we can expect the legalization of marijuana at the federal level, even for medicinal uses, to be a steep uphill battle.

Under federal law, cannabis is on the same level as controlled substances, like cocaine and heroin. Every controlled substance is classified by schedule based on relative potential for abuse and medicinal value. Under the CSA, cannabis is classified as a Schedule 1 drug, meaning the federal government views cannabis as highly addictive and having no medical value. (SafeAccessNow.org)

These strict federal laws can make it more difficult for researchers to legally obtain the necessary supply of marijuana for their trials. The difficulty of obtaining a legal supply puts any planned research at a hard stop with no chance of moving forward. Essentially, we’re currently experiencing a catch-22, with the federal government refusing to legalize marijuana based on its Schedule 1 standing and the need to obtain marijuana legally for clinical trials to prove this view unsound.

In fact, if one were to conduct a clinical trial, they would have an easier time conducting research on drugs such as ecstasy or magic mushrooms. Clinical researchers can request the ability to grow or create restricted compounds, including LSD, MDMA or psilocybin, in their lab from the DEA. Unfortunately, this is not the case with cannabis.

As expected, these classifications and restrictions on marijuana are causing a variety of frustrations across the medical community. Many researchers have noted that research is “hindered by a complicated federal approval process, limited availability of research grad marijuana and the debate over legalization.” (SafeAccessNow.org) Although we have these restrictions by the federal government, scientists are still working towards the ability to conduct sufficient research on marijuana and will continue their efforts as much as possible while following the law.

What’s an Alternative?

Since it can be difficult to locate information about the safety and effect of cannabis on the human body, how are physicians supposed to know if prescribing medical marijuana is right for their patients? Enter: Arfinn Med. Many physicians who believe in the therapeutic power of medical marijuana are beginning to try alternative treatment plans with their patients. Arfinn Med provides a portal for these physicians to track and store data to be analyzed. Additionally, physicians have the ability to consult and connect with a nationwide network of medical professionals to discuss actual experiences regarding patient outcomes.

If you are a licensed medical professional and interested in gaining more data on medical marijuana or and what it can do for your patients, join Arfinn Med for FREE today! Let us help you start treating your patients with the power of data on your side.  

Sources: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

https://www.safeaccessnow.org/federal_marijuana_law

https://www.safeaccessnow.org/medical_cannabis_research_what_does_the_evidence_say

https://www.cmcr.ucsd.edu/

Stories you may be interested in

Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness

When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s…
Read More

Medical marijuana helped elderly with chronic pain and reduced their use of opioids, study found

Your grandparents’ chronic aches and pains might best be eased with a little weed, a new study suggests. Not only did folks over 75 who took medical marijuana report less pain, their use of pot-based capsules, tinctures and e-cigarettes allowed a third of these patients to reduce their use of opioid painkillers, researchers found. “Medical marijuana, in…
Read More

DeSantis OKs telehealth for Florida medical marijuana patients

TAMPA, Fla. (WFLA) — Florida Gov. Ron DeSantis signed a bill allowing the state’s 828,000 medical marijuana patients to use telehealth to visit their doctors. On Monday, DeSantis signed HB-387, titled “Medical Use of Marijuana,” which allows patients renewing their medical marijuana recommendation to meet with their doctors online. Currently, patients must visit their doctor in person…
Read More

World Cancer Day – Shine a Light on the World

In 2018, it was estimated that 1,735,350 new cancer cases would be diagnosed in the United States and 609,640 individuals would pass from the disease [Cancer.gov]. We cannot sit by and ignore this life altering disease, which is why World Cancer Day, recognized on Feb. 4, is such an important awareness campaign to the Arfinn…
Read More

Data Migration During EMR Changes

One of the most challenging aspects when deciding to switch to a new EMR system is how to get existing data from the old system to the new system safely, securely and accurately.  Many times, the scope of this task is enough to force providers to remain with a subpar vendor even though there are…
Read More

Medical marijuana: Florida House seeks to intervene in ‘monumental’ case

TALLAHASSEE — Florida House leaders should be able to participate in a lawsuit that could revolutionize the state’s medical marijuana market, a lawyer for the Republican-led chamber told a three-judge panel of the 1st District Court of Appeal Tuesday. But Tampa-based Florigrown argued that legislators instead should concentrate on fixing the law, aimed at carrying…
Read More